Girish M. Nair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Girish M. Nair has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Calum J. Redpath
1 shared publicationCarlos A. Morillo
Division of Cardiology, Arrhythmia Service, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
1 shared publication- David Hugh Birnie
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
1 shared publication Jeffrey S. Healey
Division of Cardiology, Arrhythmia Service, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
1 shared publicationPablo B. Nery
Division of Cardiology, Arrhythmia Service, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
1 shared publication- Pablo B. Nery
Arrhythmia Service, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Canada
1 shared publication
Latest Publications
- 1 March 2014
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 29 (2) , 152-159
Ventricular arrhythmias in patients with heart failure secondary to reduced ejection fraction
To review the management of ventricular arrhythmias in patients with heart failure secondary to reduced ejection fraction (HFrEF). Recurrent ventricular arrhythmias and automatic implantable cardioverter defibrillator (AICD) shocks are responsible for significant mortality and morbidity in patients with HFrEF. Antiarrhythmic drugs and catheter ablation are the main treatment options. Frequent premature ventricular contractions (PVCs; >10,000-20,000/24-h period) are being recognized as a cause of cardiomyopathy and suboptimal response to cardiac resynchronization therapy (CRT). Patients with ventricular assist devices (VADs) have frequent ventricular tachyarrhythmias resulting in increased morbidity and mortality. Such patients may need continuation of active ICD therapy and adjunctive catheter ablation. There is a pressing need to develop new antiarrhythmic drugs to treat patients with recurrent AICD shocks. The effectiveness of catheter ablation as first-line therapy for preventing ventricular arrhythmias and recurrent AICD shocks needs to be directly compared with amiodarone. Ventricular tachyarrhythmias are common in CRT patients and patients with VADs. Frequent PVCs may result in a reversible form of HFrEF.
- 1 March 2014
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 29 (2) , 152-159
Ventricular arrhythmias in patients with heart failure secondary to reduced ejection fraction
To review the management of ventricular arrhythmias in patients with heart failure secondary to reduced ejection fraction (HFrEF). Recurrent ventricular arrhythmias and automatic implantable cardioverter defibrillator (AICD) shocks are responsible for significant mortality and morbidity in patients with HFrEF. Antiarrhythmic drugs and catheter ablation are the main treatment options. Frequent premature ventricular contractions (PVCs; >10,000-20,000/24-h period) are being recognized as a cause of cardiomyopathy and suboptimal response to cardiac resynchronization therapy (CRT). Patients with ventricular assist devices (VADs) have frequent ventricular tachyarrhythmias resulting in increased morbidity and mortality. Such patients may need continuation of active ICD therapy and adjunctive catheter ablation. There is a pressing need to develop new antiarrhythmic drugs to treat patients with recurrent AICD shocks. The effectiveness of catheter ablation as first-line therapy for preventing ventricular arrhythmias and recurrent AICD shocks needs to be directly compared with amiodarone. Ventricular tachyarrhythmias are common in CRT patients and patients with VADs. Frequent PVCs may result in a reversible form of HFrEF.
- 29 January 2009
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 20 (2) , 138-144
A Systematic Review of Randomized Trials Comparing Radiofrequency Ablation with Antiarrhythmic Medications in Patients with Atrial Fibrillation
Introduction: Atrial fibrillation (AF) is the most frequent arrhythmia seen in clinical practice. Until recently, antiarrhythmic medications have been the only commonly employed treatment for maintaining sinus rhythm. However, antiarrhythmic medications have a modest long‐term efficacy and the potential for serious side effects. Radiofrequency (RF) ablation is now emerging as a viable alternative to antiarrhythmic medications in maintaining sinus rhythm in patients with AF. Several randomized trials comparing RF ablation with antiarrhythmic medications have now been published. Objectives: To perform a systematic review of published randomized trials comparing RF ablation with antiarrhythmic medications in the treatment of AF. Methods: A systematic review of the literature was performed and two authors independently abstracted the data from trials. A statistical analysis was performed using Comprehensive Meta‐Analysis Software™ (BIOSTAT, Englewood, NJ, USA). Results: A total of six trials were identified. Overall, RF ablation reduced the risk of AF recurrence by 65% at 1 year compared with antiarrhythmic medications. Conclusions: In selected patients with AF, RF ablation reduced the risk of AF recurrence at 1 year by 65% compared with antiarrhythmic medications.
- 29 January 2009
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 20 (2) , 138-144
A Systematic Review of Randomized Trials Comparing Radiofrequency Ablation with Antiarrhythmic Medications in Patients with Atrial Fibrillation
Introduction: Atrial fibrillation (AF) is the most frequent arrhythmia seen in clinical practice. Until recently, antiarrhythmic medications have been the only commonly employed treatment for maintaining sinus rhythm. However, antiarrhythmic medications have a modest long‐term efficacy and the potential for serious side effects. Radiofrequency (RF) ablation is now emerging as a viable alternative to antiarrhythmic medications in maintaining sinus rhythm in patients with AF. Several randomized trials comparing RF ablation with antiarrhythmic medications have now been published. Objectives: To perform a systematic review of published randomized trials comparing RF ablation with antiarrhythmic medications in the treatment of AF. Methods: A systematic review of the literature was performed and two authors independently abstracted the data from trials. A statistical analysis was performed using Comprehensive Meta‐Analysis Software™ (BIOSTAT, Englewood, NJ, USA). Results: A total of six trials were identified. Overall, RF ablation reduced the risk of AF recurrence by 65% at 1 year compared with antiarrhythmic medications. Conclusions: In selected patients with AF, RF ablation reduced the risk of AF recurrence at 1 year by 65% compared with antiarrhythmic medications.